

October 27, 2016



Oculus Innovative Sciences Announces Fiscal Second Quarter 2017 Financial Results and Conference Call

PETALUMA, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal second quarter 2017, ended September 30, 2016, will be released after the U.S. markets close on November 10, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 10, 2016, to discuss fiscal second quarter results.

Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at <http://ir.oculusis.com/events.cfm>.

A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 94494840. A webcast replay will be available on the site at <http://ir.oculusis.com/events.cfm> for one year following the call.

About Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.

Media and Investor Contact:

Oculus Innovative Sciences, Inc.

Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com

Primary Logo



Source: Oculus Innovative Sciences, Inc.